Paper Proffered Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Dual Path Networks for Voxel-Level Prediction of Mid-Chemoradiotherapy Response In FDG PET for Locally Advanced Non-Small Cell Lung Cancer

Abstract
Purpose

Accurate prediction of tumor response during chemoradiotherapy is essential for treatment optimization but remains challenging. We developed a deep learning model based on a Dual Path Network (DPN), which is a hybrid architecture combining elements of ResNet and DenseNet and designed with a voxel-level output structure to predict tumor response on FDG PET imaging during treatment.

Methods

25 locally advanced non-small cell lung cancer patients undergoing chemoradiotherapy on the clinical trial (NCT02773238) were included in the analysis. We employed a deep learning architecture based on DPN to predict voxel-wise mid-treatment SUV (MidSUV) and voxel-wise mid-treatment SUV response ratio, calculated from the MidSUV and pre-treatment SUV (PreSUV) as ΔSUV (ΔSUV = (PreSUV - MidSUV)/PreSUV). We implemented a leave-one-out cross-validation strategy across 25 patients, resulting in 25 rounds of experiments. In each round, one patient was sequentially selected as the test patient. From the remaining cohort, one patient from each of the three response categories (classified according to SUV changes: high [n=8], medium [n=8], and low [n=9]) was randomly selected to form the validation set, while the rest comprised the training set. Prediction accuracy was quantified using the root mean squared error (RMSE) and the mean absolute error (MAE) between predicted and reference values, and Spearman's rank correlation coefficient was used to assess monotonic association; all metrics were computed for both voxel-wise MidSUV and ΔSUV predictions.

Results

Evaluating the best-performing model from each validation round, the RMSE was 1.26 for MidSUV and 0.26 for ΔSUV, while the MAE was 0.99 and 0.19. Spearman’s rank correlation coefficient was 0.69 for MidSUV and 0.15 for ΔSUV across all patients.

Conclusion

In this study, we employed DPN to predict lung tumor response following chemoradiotherapy. By utilizing an innovative network architecture, we achieved voxel-level prediction capability, which can guide future patient-level treatment strategies.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested